Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
46.8M
-
Number of holders
-
68
-
Total 13F shares, excl. options
-
7.93M
-
Shares change
-
-458K
-
Total reported value, excl. options
-
$42.3M
-
Value change
-
-$3.22M
-
Put/Call ratio
-
0.04
-
Number of buys
-
34
-
Number of sells
-
-17
-
Price
-
$5.34
Significant Holders of Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share (OTLK) as of Q3 2024
76 filings reported holding OTLK - Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share as of Q3 2024.
Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share (OTLK) has 68 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.93M shares
of 46.8M outstanding shares and own 16.96% of the company stock.
Largest 10 shareholders include TANG CAPITAL MANAGEMENT LLC (1.56M shares), GREAT POINT PARTNERS LLC (1.29M shares), BlackRock, Inc. (1.04M shares), VANGUARD GROUP INC (856K shares), Altium Capital Management LP (542K shares), SPHERA FUNDS MANAGEMENT LTD. (414K shares), GEODE CAPITAL MANAGEMENT, LLC (342K shares), Caligan Partners LP (319K shares), Schonfeld Strategic Advisors LLC (286K shares), and STATE STREET CORP (233K shares).
This table shows the top 68 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.